John Scarlett's plan to reinvent Geron as a developer of new and exciting cancer drugs has slammed into a fresh debacle.
Will Abraxane join the new gang of melanoma fighters?
Just 10 months after new Geron CEO John Scarlett dumped a decade's worth of stem cell work in favor of a special focus on cancer drugs, the biotech has written off a pair of lead drug studies after tracking discouraging progression-free survival data in Phase II.
Cephalon is paying out $10 million to acquire the IP rights to Acusphere's Hydrophobic Drug Delivery
Avanti Therapeutics launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee will use Avanti's drug delivery technology to enhance the performance of
> According to research released today, the anti-rheumatoid arthritis med Enbrel has shown an amazing ability to rehabilitate Alzheimer's patients.
Perhaps the second time is the charm for Genentech. The biotech has re-submitted a sBLA to the FDA for Avastin in combination with paclitaxel chemotherapy as a first-line treatment for metastatic
Press Release: Phase III Trial of Nexavar Does Not Meet Primary Endpoint
The FDA has granted Synta Pharmaceuticals fast-track status for its lead oncology drug candidate, STA-4783 . In a recently completed, Phase IIb clinical trial in patients with Stage IV metastatic malignant melanoma, treatment with STA-4783 plus paclitaxel achieved the primary endpoint of increasing progression-free survival. Synta was a 2004 …
Synta Pharmaceuticals gets FDA Fast Track Designation for STA-4783